These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20493453)

  • 1. [Chemotherapy with docetaxel in prostate cancer. A case report].
    Lechevallier E; Culine S; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S80-3. PubMed ID: 20493453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate cancer: future strategies for chemotherapy management].
    Fizazi K
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S77-9. PubMed ID: 18297905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Docetaxel for metastatic prostate cancer: early is better].
    Gietema JA; Oosting SF
    Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
    Sonpavde G; Sternberg CN
    Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
    Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
    Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
    Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
    DeGrendele H
    Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
    [No Abstract]   [Full Text] [Related]  

  • 9. The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
    Gupta K; Elkon J; El-Bahesh E; Aragon-Ching JB
    Anticancer Agents Med Chem; 2016; 16(9):1166-71. PubMed ID: 24359499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
    Gallardo E; Arranz JÁ; Maroto JP; León LÁ; Bellmunt J
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):357-67. PubMed ID: 23867574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
    Harrington JA; Jones RJ
    Eur J Cancer; 2011 Sep; 47(14):2133-42. PubMed ID: 21658937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
    BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
    Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
    Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy for prostate cancer].
    Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
    Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
    Fizazi K; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houedé N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Lagrange JL; Chinet-Charrot P; Linassier C; Deplanque G; Beuzeboc P; Geneve J; Davin JL; Tournay E; Culine S
    Eur J Cancer; 2012 Jan; 48(2):209-17. PubMed ID: 22119204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
    BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.
    Sinibaldi VJ
    Clin Interv Aging; 2007; 2(4):555-60. PubMed ID: 18225455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
    Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
    Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.